Phase 4
N=19
Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Bottom Line
View on ClinicalTrials.gov: NCT01460225 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- lubiprostone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Gastric Emptying |
0.27; 0.384; 0.04; 0.051 | 0.003 sig |
Summary
This prospective study is designed to evaluate how lubiprostone may affect gastric motor and sensory function.
Eligibility Criteria
Inclusion Criteria
- chronic idiopathic constipation
Exclusion Criteria
- medications that slow gastrointestinal (GI) motility
- prior surgery to the GI tract
Data sourced from ClinicalTrials.gov (NCT01460225). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.